Monthly Archives: October 2012
By Guest Blogger | Published: October 24, 2012
The sudden departure of EC Health Commissioner John Dalli tops an already difficult year for the European pharma regulators, writes Reflector. The abrupt departure of Health Commissioner John Dalli in highly controversial circumstances comes on top of an extremely difficult year for the European Medicines Agency (EMA). At the same time, one of the main supervisory bodies [...]
By Guest Blogger | Published: October 19, 2012
By Ansis Helmanis Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry. This was the consensus of FDA Commissioner Margaret Hamburg and European Medicines Agency (EMA) Executive Director Guido Rasi, both of whom shared the podium with Nobel Laureate Professor Elie Wiesel [...]
By Clark Herman | Published: October 18, 2012
Featured panelists at ExL’s annual Digital Pharma East conference this week included practicing physicians, vocal ePatients, social media gurus and digital marketing consultants with plenty of hours logged in big pharma boardrooms.
By Ben Comer | Published: October 17, 2012
FDA’s head of neurology products told industry execs at the Prix Galien Forum that the agency is open to alternative clinical trial designs in Alzheimer’s disease, and would like to see more combination products in clinical testing.
By Guest Blogger | Published: October 17, 2012
By David L. Rosen New stories earlier this year (1) reported that FDA scientists have been suspected of leaking confidential, commercial, and trade secret information to the media.